BridgeBio has demonstrably improved this progress of the new treatment for amyloid heart disease, leveraging the investigational drug. Preliminary clinical information reveals potential improvements for those affected with this severe condition. The focus represents the company’s focus to managing significant healthcare demands in a heart space.